Figure 6
From: Generation of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines
Anti-cancer drug screening in CDS cells. (a) NCC-CDS1-X1-C1 and X3-C1 cells were treated with 119 FDA approved anti-cancer compounds (10 μM) for 72 h. (b–j) Viability of the cells treated with anti-cancer drugs, including actinomycin D, bortezomib, daunorubicin, idarubicin, topotecan, camptothecin, epirubicin, doxorubicin, and crizotinib. (k) The IC50 value is shown for each anti-cancer drug.
